The effect of a liver-X-receptor ligand on bleomycin induced pulmonary fibrosis in mice |
| |
| Affiliation: | 1. Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China;2. Yancheng City No. 1 People''s Hospital, Yan Cheng, China;1. Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland;2. The Medical University of Silesia, School of Pharmacy with the Division of Laboratory Medicine, Department of Organic Chemistry, Jagiellońska 4, 41-200 Sosnowiec, Poland;1. Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, China;2. Department of Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, China;1. Department of Rheumatology, Shenzhen Children''s Hospital, Affiliated with Chongqing Medical University, China;2. Department of Rheumatology, Chongqing Children''s Hospital, Affiliated with Chongqing Medical University, China |
| |
| Abstract: | The liver-X-receptors have shown anti-fibrosis ability in several animal models. Our purpose was to investigate the effect of LXRs in bleomycin induced lung fibrosis in mice. Bleomycin was intratracheally delivered to mice. Some mice were administered a LXR agonist, T0901317. Then mice were evaluated for the development of lung inflammation and fibrosis. T0901317 was able to attenuate the inflammation and fibrosis induced by bleomycin. T0901317 treatment evidently abolished the high level of TGF-β1 and inhibited NF-κB DNA-binding activity in lung. So LXRs may attenuate the progressing of lung fibrosis, providing a potential treatment of IPF. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
